Latest Breaking News On - Susana noonan - Page 3 : comparemela.com

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in r/r B-ALLThe US marketing application is under review with a Prescription Drug User Fee Act target action date of.

United kingdomUnited statesCity ofJulia wilsonSusana noonanOlivia manserSa noonan communicationsCompany marketing authorization applicationExchange commissionEuropean medicines agencyPrescription drug user fee actMarketing authorization applicationB cell acute lymphoblastic leukemiaChristian itinChief executive officerOrphan drug designation

Autolus Therapeutics Announces Changes to its Board of Directors

LONDON, April 01, 2024 Autolus Therapeutics plc , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the appointment of Mike.

United kingdomCity ofMike bonneyRavi raoOlivia manserOxford biomedicaJohnh johnsonRoche genentechSusana noonanJulia wilsonCambridge universityHarvard medical schoolExchange commissionGulf of maine research instituteDrug administrationImperial college london

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA)

LONDON, March 12, 2024 (GLOBE NEWSWIRE) Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that following the most recent GMP

United statesUnited kingdomCity ofSusana noonanOlivia manserDave brochuJulia wilsonExchange commission onSa noonan communicationsExchange commissionAutolu nucleusImportation authorisationChief technology officerOrphan drug designationOrphan medical product designationRegenerative medicine advanced therapy

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomSusana noonanJulia wilsonOlivia manserSa noonan communicationsThursday march

Autolus Therapeutics announces publication in Nature Communications

LONDON, Feb. 22, 2024 Autolus Therapeutics plc , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces a publication in Nature.

City ofUnited kingdomLauren williamsJulia wilsonSusana noonanOlivia manserNature communicationsExchange commission onExchange commissionSa noonan communicationsStructure guided engineeringAutolus therapeuticsPrivate securities litigation reform actAutolu annual reportAutolu quarterly report